Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Rises By 1,185.7%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 9,000 shares, an increase of 1,185.7% from the June 30th total of 700 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily volume of 58,000 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Galmed Pharmaceuticals in a research note on Sunday, July 21st. They set a “sell” rating on the stock.

Galmed Pharmaceuticals Price Performance

Shares of GLMD stock opened at $0.31 on Friday. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.26. The stock’s 50-day simple moving average is $0.33 and its 200-day simple moving average is $0.36.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.